Olympus chief executive Bob White told investors on November 13 that the company has stepped up remediation and quality work since January and that it already sees progress on the areas FDA has flagged. He said the issues in the latest warning letter will help confirm that completed work holds up and will sharpen the approach going forward.
FDA issued that warning letter in October 2026 over quality system violations, citing inspections at six facilities in Japan, Europe and the US carried out in late 2025. The agency added five more devices to the denied-entry list and issued import alerts covering further Japan-made endoscope models. It follows three warning letters in 2022 and 2023 and a June 2025 action that blocked 58 endoscope models from the US, which cost roughly 9 billion yen (about $56M) in consolidated revenue.
Second quarter revenue for fiscal 2027 rose 9 percent to 269.2 billion yen (about $1.68B), and Olympus raised full-year guidance for revenue, adjusted operating margin and adjusted earnings per share. White, who joined in June 2025 from Medtronic, said the company has recruited quality and operations leaders and added FDA regulatory headcount. Olympus set no public remediation timeline.
The pattern here is worth sitting with: four warning letters over four years, and the company's own framing is that the newest one validates earlier fixes. Sustained evidence, not corrective action closure, is what the agency is asking for, and that is a longer clock than most remediation plans assume.